Wegovy vs. Zepbound: The 2026 Update
Both FDA-approved GLP-1s for weight loss dropped prices aggressively in late 2025. Zepbound still leads on clinical outcomes; Wegovy now edges it on price for 12-month commitments. Here's the updated verdict.
The Verdict
Zepbound wins on weight loss magnitude — SURMOUNT-5 head-to-head showed tirzepatide producing greater weight loss than semaglutide. Wegovy wins on price for committed patients ($249/mo on 12-month Novo subscription vs. Zepbound's $299–449 vial range). Wegovy also wins on CV outcomes — it's the only obesity GLP-1 with FDA-approved cardiovascular risk reduction labeling. Pick Zepbound for maximum weight loss. Pick Wegovy for predictable pricing and CV benefit.
Late 2025 and early 2026 produced a price war between Novo Nordisk and Eli Lilly that permanently reshaped the branded GLP-1 market. Both companies slashed cash-pay prices to compete with compounded alternatives and with each other. Understanding where these two sit now — pricing, outcomes, format — matters if you're choosing between them in 2026.
Current pricing (April 2026)
| Option | Wegovy | Zepbound |
|---|---|---|
| Cash price (direct from manufacturer) | $349/mo all doses (NovoCare) | $299–449/mo (vials, LillyDirect) |
| 12-month subscription (lowest) | $249/mo | Not yet offered |
| 6-month subscription | $299/mo | N/A |
| 3-month subscription | $329/mo | N/A |
| Available via telehealth | Ro, WW, Hims, LifeMD, Sesame | Sesame, telehealth partners |
| Pen vs. vial | Pen (easier injection) | Vial (lower cost) or pen (standard) |
Clinical outcomes: Zepbound's edge
Phase 3 trial data favors Zepbound on the key efficacy metric — total weight loss. In SURMOUNT-5, the head-to-head trial of tirzepatide vs. semaglutide for obesity, tirzepatide produced meaningfully greater weight loss over 72 weeks.
- Wegovy (STEP 1): ~15% average weight loss at 68 weeks.
- Zepbound (SURMOUNT-1): ~21% average weight loss at 72 weeks (15mg dose).
- Head-to-head (SURMOUNT-5): Tirzepatide significantly outperformed semaglutide on weight loss at all comparable timepoints.
For patients whose primary goal is maximum weight reduction, Zepbound is the clinically superior choice. The ~6 percentage-point difference translates to roughly 15 extra pounds lost for a 250-pound person.
Wegovy's unique strength: CV outcomes
The SELECT trial established that Wegovy reduces major adverse cardiovascular events (MACE) by ~20% in overweight/obese patients with established cardiovascular disease. Zepbound doesn't yet have equivalent outcomes data (Lilly's SURMOUNT-MMO trial is ongoing).
For patients with existing heart disease, history of heart attack or stroke, or strong CV risk factors, Wegovy's FDA-approved CV risk reduction indication is a meaningful differentiator — and often the factor that tips insurance coverage in Wegovy's favor.
Pricing math: 12-month cost comparison
- Wegovy, 12-month subscription: $249 × 12 = $2,988
- Wegovy, cash via NovoCare: $349 × 12 = $4,188
- Zepbound vials (2.5mg): $299 × 12 = $3,588
- Zepbound vials (mid-dose 7.5–10mg): $399 × 12 = $4,788
- Zepbound pens (standard): ~$1,060/mo retail = $12,720 without discounts
For price-sensitive patients committing to 12 months, Wegovy's subscription makes it the cheaper branded option. For patients who want vials and can work with Zepbound's 45-day refill rule, Lilly's direct pricing is competitive.
Side effect profiles
Both medications share similar side effect profiles — nausea, vomiting, constipation, diarrhea, abdominal pain. Clinical trials show:
- Zepbound: Slightly higher rates of nausea and diarrhea at higher doses. Overall discontinuation rates comparable.
- Wegovy: Slightly higher rates of vomiting. Overall discontinuation rates comparable.
In practice, patient tolerance varies individually more than between medications. Patients who don't tolerate one often tolerate the other reasonably well.
Who should pick Wegovy
Who should pick Zepbound
What's coming later in 2026
- Lilly's oral tirzepatide (orforglipron): Currently under FDA review; expected launch late 2026. Will compete directly with oral Wegovy.
- Wegovy HD 7.2mg high-dose injection: Recently FDA-approved; subscription inclusion coming.
- Medicare coverage changes: White House-negotiated 71% Medicare discount on Ozempic and Wegovy effective 2027.
- Zepbound subscription program: Not announced, but likely response if Wegovy gains meaningful market share.
Bottom line
Both Wegovy and Zepbound are excellent medications with strong clinical evidence. The choice between them in 2026 has become more about fit than superiority: Zepbound for maximum weight loss, Wegovy for predictable pricing and CV benefit. Neither is a wrong answer for most patients. Access (insurance, telehealth availability) often decides more than clinical preference.